Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2017 (15).
- Resumption after record date
Trading of the shares of the Company will resume on 16.11.2017 after record date.
- Suspension for Record Date
Trading of the shares of the Company will remain suspended on record date i.e., 15.11.2017.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.59 for July-September, 2017 as against Tk. 1.27 for July-September, 2016; NOCFPS was Tk. 1.56 for July-September, 2017 as against Tk. 1.62 for July-September, 2016. NAV per share was Tk. 63.36 as on September 30, 2017 and Tk. 60.97 as on September 30, 2016.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 13.11.2017 to 14.11.2017. Trading of the shares of the Company will remain suspended on record date i.e., 15.11.2017.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2017 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2017.
- Dividend Declaration
The Board of Directors has recommended 12.50% cash dividend for the year ended on June 30, 2017. Date of AGM: 23.12.2017, Time: 10:00 AM, Venue: Beximco Industrial Park, Sarabo, Kashimpur, Gazipur. Record Date: 15.11.2017. (cont.) (Continuation news of BXPHARMA): The Company has also reported EPS of Tk. 5.49, NAV per share of Tk. 61.82 and NOCFPS of Tk. 6.49 for the year ended on June 30, 2017 whereas EPS of Tk. 7.27 and NOCFPS of Tk. 8.21 for the 18 months period from January 01, 2015 to June 30, 2016. NAV per share was Tk. 59.70 as on June 30, 2016. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (26.10.2017) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 25, 2017 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2017.
- Signed a MOU to acquire stake in Nuvista Pharma Ltd.
The Company has informed that the Board of Directors of the Company has decided to enter into a non-binding Memorandum of Understanding (MOU) under which Beximco Pharma may acquire a majority shareholding (85.22%) in Nuvista Pharma Ltd. a leading pharma Company in Bangladesh specializing in hormones and steroid drugs (the proposed acquisition). The proposed acquisition remains subject to due diligence and negotiation and completion of a definitive Sale and Purchase Agreement. (cont. 1) (continuation news of BXPHARMA): with a local manufacturing facility at Tongi, Gazipur. They also have a long-term manufacturing and marketing collaboration with Merck Sharp & Dohme (MSD). According to the Quintiles IMS Q2 2017 data of the retail pharma market in Bangladesh, Nuvista Pharma currently ranks as the 21st largest supplier to the market by volume. (end) (continuation news of BXPHARMA): It is expected that the Proposed Acquisition will be completed by the end of December 2017 and will, if completed, accelerate revenue growth and improve the earning potential for Beximco Pharma. The Company has further informed that Nuvista Pharma Ltd, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. It was sold out to the current Bangladeshi Management in 2006. The Company has been operating in Bangladesh since 1964 (cont. 2)
- Credit Rating Result
Credit Rating Information and Services Limited (CRISL) has rated the Company as "AA+" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2016, unaudited financials up to March 31, 2017 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 1.29 for January-March, 2017 as against Tk. 1.06 for January-March, 2016; EPS was Tk. 4.03 for July, 2016-March, 2017 as against Tk. 3.39 for July, 2015-March, 2016. NOCFPS was Tk. 4.37 for July, 2016-March, 2017 as against Tk. 4.77 for July, 2015-March, 2016. NAV per share was Tk. 60.36 as of March 31, 2017 and Tk. 59.24 as of March 31, 2016.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 27, 2017 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.
- Query Response
In response to a DSE query dated April 05, 2017, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike.
- Q2 Financials
EPS was Tk. 1.47 for October-December, 2016 as against Tk. 1.29 for October-December, 2015; EPS was Tk. 2.74 for July-December, 2016 as against Tk. 2.33 for July-December, 2015. NOCFPS was Tk. 2.56 for July-December, 2016 as against Tk. 3.28 for July-December, 2015. NAV per share was Tk. 59.07 as of December 31, 2016 and Tk. 58.20 as of December 31, 2015.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 26, 2017 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.